Effect of Sarcopenia on the Increase in Liver Volume and Function After Portal Vein Embolization.

Hepatobiliary scintigraphy Liver function Portal vein embolization Sarcopenia

Journal

Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538

Informations de publication

Date de publication:
28 Feb 2024
Historique:
received: 05 10 2023
accepted: 28 01 2024
medline: 28 2 2024
pubmed: 28 2 2024
entrez: 28 2 2024
Statut: aheadofprint

Résumé

Sarcopenia is associated with a decreased kinetic growth rate (KGR) of the future liver remnant (FLR) after portal vein embolization (PVE). However, little is known on the increase in FLR function (FLRF) after PVE. This study evaluated the effect of sarcopenia on the functional growth rate (FGR) after PVE measured with hepatobiliary scintigraphy (HBS). All patients who underwent PVE at the Amsterdam UMC between January 2005 and August 2017 were analyzed. Functional imaging by HBS was used to determine FGR. Liver volumetry was performed using multiphase contrast computed tomography (CT). Muscle area measurement to determine sarcopenia was taken at the third lumbar level (L3). Out of the 95 included patients, 9 were excluded due to unavailable data. 70/86 (81%) patients were sarcopenic. In the multivariate logistic regression analysis, sarcopenia (p = 0.009) and FLR volume (FRLV) before PVE (p = 0.021) were the only factors correlated with KGR, while no correlation was found with FGR. 90-day mortality was similar across the sarcopenic and non-sarcopenic group (4/53 [8%] versus 1/11 [9%]; p = 1.000). The resection rates were also comparable (53/70 [75%] versus 11/16 [69%]; p = 0.542). FGR after PVE as measured by HBS appears to be preserved in sarcopenic patients. This is in contrast to KGR after PVE as measured by liver volumetry which is decreased in sarcopenic patients. Level 3b, cohort and case control studies.

Identifiants

pubmed: 38416177
doi: 10.1007/s00270-024-03676-2
pii: 10.1007/s00270-024-03676-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Abdalla EK, Barnett CC, Doherty D, et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg. 2002;137(6):675–81.
pubmed: 12049538
De Meijer V, Kalish B, Puder M, IJzermans J. Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg. 2010;97(9):1331–9.
pubmed: 20641066
Ferrero A, Viganò L, Polastri R, et al. Postoperative liver dysfunction and future remnant liver: where is the limit? World J Surg. 2007;31(8):1643–51.
pubmed: 17551779
Imamura H, Sano K, Sugawara Y, et al. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg. 2005;12(1):16–22.
pubmed: 15754094
Shoup M, Gonen M, D’Angelica M, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg. 2003;7(3):325–30.
pubmed: 12654556
Glantzounis G, Tokidis E, Basourakos S-P, et al. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. Eur J Surg Oncol. 2017;43(1):32–41.
pubmed: 27283892
Massimino KP, Kolbeck KJ, Enestvedt CK, et al. Safety and efficacy of preoperative right portal vein embolization in patients at risk for postoperative liver failure following major right hepatectomy. HPB. 2012;14(1):14–9.
pubmed: 22151446 pmcid: 3252986
Olthof PB, Wiggers JK, Koerkamp BG, et al. Postoperative liver failure risk score: identifying patients with resectable perihilar cholangiocarcinoma who can benefit from portal vein embolization. J Am Coll Surg. 2017;225(3):387–94.
pubmed: 28687509
Van Lienden K, Van Den Esschert J, De Graaf W, et al. Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol. 2013;36(1):25–34.
pubmed: 22806245
Wajswol E, Jazmati T, Contractor S, Kumar A. Portal vein embolization utilizing N-butyl cyanoacrylate for contralateral lobe hypertrophy prior to liver resection: a systematic review and meta-analysis. Cardiovasc Intervent Radiol. 2018;41(9):1302–12.
pubmed: 29687262
Guglielmi A, Ruzzenente A, Conci S, et al. How much remnant is enough in liver resection? Dig Surg. 2012;29(1):6–17.
pubmed: 22441614
Shindoh J, Truty MJ, Aloia TA, et al. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg. 2013;216(2):201–9.
pubmed: 23219349
Olthof PB, Tomassini F, Huespe PE, et al. Hepatobiliary scintigraphy to evaluate liver function in associating liver partition and portal vein ligation for staged hepatectomy: liver volume overestimates liver function. Surgery. 2017;162(4):775–83.
pubmed: 28732555
Sparrelid E, Jonas E, Tzortzakakis A, et al. Dynamic evaluation of liver volume and function in associating liver partition and portal vein ligation for staged hepatectomy. J Gastrointest Surg. 2017;21(6):967–74.
pubmed: 28283924 pmcid: 5443865
Rassam F, Olthof PB, van Lienden KP, et al. Functional and volumetric assessment of liver segments after portal vein embolization: differences in hypertrophy response. Surgery. 2019;165(4):686–95.
pubmed: 30573191
Bennink RJ, Dinant S, Erdogan D, et al. Preoperative assessment of postoperative remnant liver function using hepatobiliary scintigraphy. J Nucl Med. 2004;45(6):965–71.
pubmed: 15181131
Cieslak KP, Bennink RJ, de Graaf W, et al. Measurement of liver function using hepatobiliary scintigraphy improves risk assessment in patients undergoing major liver resection. HPB. 2016;18(9):773–80.
pubmed: 27593595 pmcid: 5011085
De Graaf W, Van Lienden KP, Dinant S, et al. Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection. J Gastrointest Surg. 2010;14(2):369–78.
pubmed: 19937195
Dinant S, de Graaf W, Verwer BJ, et al. Risk assessment of posthepatectomy liver failure using hepatobiliary scintigraphy and CT volumetry. J Nucl Med. 2007;48(5):685–92.
pubmed: 17475954
Dello SA, Lodewick TM, van Dam RM, et al. Sarcopenia negatively affects preoperative total functional liver volume in patients undergoing liver resection. HPB. 2013;15(3):165–9.
pubmed: 23020663 pmcid: 3572275
Harimoto N, Shirabe K, Yamashita Y, et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. J Br Surg. 2013;100(11):1523–30.
Miyamoto Y, Baba Y, Sakamoto Y, et al. Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer. Ann Surg Oncol. 2015;22(8):2663–8.
pubmed: 25564158
Heil J, Heid F, Bechstein WO, et al. Sarcopenia predicts reduced liver growth and reduced resectability in patients undergoing portal vein embolization before liver resection-A DRAGON COLLABORATIVE analysis of 306 patients. HPB. 2021;24:413–21.
pubmed: 34526229
Peng PD, Van Vledder MG, Tsai S, et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB. 2011;13(7):439–46.
pubmed: 21689226 pmcid: 3133709
Vandenbroucke JP, Von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297.
pubmed: 17941715 pmcid: 2020496
Vauthey J-N, Abdalla EK, Doherty DA, et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl. 2002;8(3):233–40.
pubmed: 11910568
Rassam F, Olthof PB, Richardson H, et al. Practical guidelines for the use of technetium-99m mebrofenin hepatobiliary scintigraphy in the quantitative assessment of liver function. Nucl Med Commun. 2019;40(4):297–307.
pubmed: 30601245
Erdogan D, Heijnen BH, Bennink RJ, et al. Preoperative assessment of liver function: a comparison of 99mTc-Mebrofenin scintigraphy with indocyanine green clearance test. Liver Int. 2004;24(2):117–23.
pubmed: 15078475
de Graaf W, Häusler S, Heger M, et al. Transporters involved in the hepatic uptake of 99mTc-mebrofenin and indocyanine green. J Hepatol. 2011;54(4):738–45.
pubmed: 21163547
Ekman M, Fjälling M, Holmberg S, Person H, editors. IODIDA clearance rate: a method for measuring hepatocyte uptake function. In: XVIth Congress of the Scandinavian Transplantation Society, Reykavik, Iceland, June 12–14, 1991. Transplantation proceedings; 1992.
Olthof PB, Coelen RJ, Bennink RJ, et al. 99mTc-mebrofenin hepatobiliary scintigraphy predicts liver failure following major liver resection for perihilar cholangiocarcinoma. HPB. 2017;19(10):850–8.
pubmed: 28687148
Nishigori T, Tsunoda S, Obama K, et al. Optimal cutoff values of skeletal muscle index to define sarcopenia for prediction of survival in patients with advanced gastric cancer. Ann Surg Oncol. 2018;25(12):3596–603.
pubmed: 30167910
Martin L, Birdsell L, MacDonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–47.
pubmed: 23530101
Denbo JW, Kim BJ, Vauthey J-N, et al. Overall body composition and sarcopenia are associated with poor liver hypertrophy following portal vein embolization. J Gastrointest Surg. 2021;25(2):405–10.
pubmed: 31997073
Schulze-Hagen M, Truhn D, Duong F, et al. Correlation Between Sarcopenia and Growth Rate of the Future Liver Remnant After Portal Vein Embolization in Patients with Colorectal Liver Metastases. Cardiovascular and interventional radiology. 2020:1–7.
Lau H, Man K, Fan ST, et al. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg. 1997;84(9):1255–9.
pubmed: 9313707
Haimerl M, Verloh N, Zeman F, et al. Gd-EOB-DTPA-enhanced MRI for evaluation of liver function: comparison between signal-intensity-based indices and T1 relaxometry. Sci Rep. 2017;7(1):43347.
pubmed: 28266528 pmcid: 5339723
Stockmann M, Lock JF, Malinowski M, et al. The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB. 2010;12(2):139–46.
pubmed: 20495659 pmcid: 2826673
Lodewick TM, Roeth AA, Olde Damink SW, et al. Sarcopenia, obesity and sarcopenic obesity: effects on liver function and volume in patients scheduled for major liver resection. J Cachexia Sarcopenia Muscle. 2015;6(2):155–63.
pubmed: 26136191 pmcid: 4458081
Otsuji H, Yokoyama Y, Ebata T, et al. Preoperative sarcopenia negatively impacts postoperative outcomes following major hepatectomy with extrahepatic bile duct resection. World J Surg. 2015;39(6):1494–500.
pubmed: 25651963
Lieffers J, Bathe O, Fassbender K, et al. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer. 2012;107(6):931–6.
pubmed: 22871883 pmcid: 3464761
van Keulen A-M, Buettner S, Besselink MG, et al. Primary and secondary liver failure after major liver resection for perihilar cholangiocarcinoma. Surgery. 2021;170:1024–30.
pubmed: 34020794
Furusawa N, Kobayashi A, Yokoyama T, et al. Surgical treatment of 144 cases of hilar cholangiocarcinoma without liver-related mortality. World J Surg. 2014;38(5):1164–76.
pubmed: 24305942
Franken L, Rassam F, van Lienden K, et al. Effect of structured use of preoperative portal vein embolization on outcomes after liver resection of perihilar cholangiocarcinoma. BJS open. 2020;4(3):449–55.
pubmed: 32181590 pmcid: 7260406
Van Vledder M, Levolger S, Ayez N, et al. Body composition and outcome in patients undergoing resection of colorectal liver metastases. J Br Surg. 2012;99(4):550–7.
Peng P, Hyder O, Firoozmand A, et al. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16(8):1478–86.
pubmed: 22692586 pmcid: 3578313
Pipek LZ, Baptista CG, Nascimento RFV, et al. The impact of properly diagnosed sarcopenia on postoperative outcomes after gastrointestinal surgery: a systematic review and meta-analysis. PLoS ONE. 2020;15(8):e0237740.
pubmed: 32822372 pmcid: 7446889
Wagner D, DeMarco MM, Amini N, et al. Role of frailty and sarcopenia in predicting outcomes among patients undergoing gastrointestinal surgery. World J Gastrointest Surg. 2016;8(1):27.
pubmed: 26843911 pmcid: 4724585
Cornet M, Lim C, Salloum C, et al. Prognostic value of sarcopenia in liver surgery. J Visc Surg. 2015;152(5):297–304.
pubmed: 26476674
Olthof PB, Aldrighetti L, Alikhanov R, et al. Portal vein embolization is associated with reduced liver failure and mortality in high-risk resections for perihilar cholangiocarcinoma. Ann Surg Oncol. 2020;27:2311–8.
pubmed: 32103419 pmcid: 7311501

Auteurs

Pieter J W Arntz (PJW)

Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Cancer Center Amsterdam, Amsterdam, The Netherlands.

Pim B Olthof (PB)

Department of Surgery, Erasmus MC, Rotterdam, The Netherlands.
Department of Surgery, University Medical Center Groningen, Groningen, The Netherlands.

Remon Korenblik (R)

GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
Department of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands.

Jan Heil (J)

Institute of Physiology, University of Zurich, Zurich, Switzerland.
Department of General, Visceral and Transplant Surgery, University Hospital Frankfurt, Goethe-University Frankfurt, Frankfurt/Main, Germany.

Geert Kazemier (G)

Cancer Center Amsterdam, Amsterdam, The Netherlands.
Department of Surgery, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.

Otto M van Delden (OM)

Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Roelof J Bennink (RJ)

Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Steven W M Olde Damink (SWMO)

GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
Department of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands.

Ronald M van Dam (RM)

GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
Department of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands.

Erik Schadde (E)

Institute of Physiology, University of Zurich, Zurich, Switzerland.
Department of Surgery, Rush University Chicago, Chicago, IL, USA.
Department of General and Visceral Surgery, Cantonal Hospital Winterthur, Winterthur, Switzerland.

Joris I Erdmann (JI)

Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. j.i.erdmann@amsterdamumc.nl.
Cancer Center Amsterdam, Amsterdam, The Netherlands. j.i.erdmann@amsterdamumc.nl.

Classifications MeSH